Visual demonstration of weight loss and health risk improvement with a dual GIP and GLP-1 receptor agonist
Authors' conclusion
Visual presentation of new weight loss medicine trial results can supplement standard published reports by condensing substantial amounts of complex technical information in an easily understood format that can potentially yield new study insights.
Study context
- Population
- Surmount 1 average male and female participants (maximal-tolerated dose group)
- Comparison
- Baseline vs 72 weeks of tirzepatide
- Outcome
- Visual representations of body size and shape
- Follow-up
- Baseline and 72 weeks
Methodological detailsvisual demonstration, manifold regression avatars, body roundness index
- Visual demonstration
- Manifold regression avatars
- Body roundness index
Main finding
As reported in the abstract
baseline and 72 weeks
- Clear excess adiposity and high health-risk (body roundness index (BRI)) at baseline, with marked improvements at 72 weeks, although not to within the healthy BMI (<25 kg/m²) and BRI ranges; not evident in the published report
- Avatar analyses revealed sexual dimorphism in regional shape (volume) changes with weight loss
Original publication
Visual demonstration of weight loss and health risk improvement with a dual GIP and GLP-1 receptor agonist. Int J Obes (Lond). Published 14 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →